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A 17-year-old male with symptoms of headache and diaphoresis presented to the emergency 
department. He had eight months of noted hypertension attributed to medications. On arrival his 
blood pressure was 229/117mmHg, and he was ill-appearing. His blood pressure was managed 
aggressively, and he was diagnosed with extra-adrenal pheochromocytoma by computed 
tomography. He eventually underwent resection of the mass. Children with severe, symptomatic 
hypertension should be evaluated for pheochromocytoma. Although rare, it is curable. Failure to 
diagnose carries a high risk of morbidity and mortality. [West J Emerg Med. 2011;12(2):258-261.]
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CASE PRESENTATION
A 17-year old African-American male presented to his 
school nurse with sudden onset of a sensation of all-over 
warmth, nausea, diaphoresis, mild headache, palpitations and 
shortness of breath. These symptoms occurred while sitting in 
class. On the nurse’s evaluation, the patient had a blood 
pressure of 260/140mmHg, so he was transferred to the 
emergency department (ED).
Upon arrival to the ED, the patient’s temperature was 
97.6°F, his heart rate was 103 beats/min, respiratory rate 17 
breaths/min, room air oxygen saturation 100% and blood 
pressure 229/117mmHg. His rhythm strip showed sinus 
tachycardia with what was believed to be likely sinus 
arrhythmia. He was diaphoretic and appeared dyspneic and ill. 
He had no thyromegaly, and pulmonary, abdominal, and 
neurological exams were all normal. His cardiac exam was 
remarkable only for tachycardia. He had no papilledema.
The patient had a past medical history of attention deficit 
hyperactive disorder for which he took 80mg of atomoxetine 
(norepinephrine uptake inhibitor) daily. He had been on this 
medication for several months. Previously, he had taken 
methylphenidate, but this had been stopped for unclear 
reasons. The patient had been noted to be hypertensive during 
a sports physical at school ten months previously, with a blood 
pressure of 180/100mmHg. He had undergone evaluation at 
that time with ultrasound of his kidneys and retroperitoneum, 
which showed no evidence of masses or renal artery stenosis. 
During the ensuing ten months, the patient had intermittent 
episodes of lightheadedness, headaches, diaphoresis and 
palpitations occurring one to two times per week and lasting 
between 15 and 60 minutes. He had been evaluated in the ED 
four months prior for lightheadedness, and at that time, the 
patient had a blood pressure of 159/99mmHg. He reported 
taking quetiapine and marijuana recreationally, and his 
elevated blood pressure was attributed to illicit substance use. 
His electrocardiogram (ECG) and chest radiograph had been 
normal, and his symptoms resolved spontaneously in the ED. 
On discharge, his blood pressure had been 141/91mmHg.
On his second ED visit, the patient’s differential diagnosis 
included pheochromocytoma, thyroid disease, renovascular 
hypertension and toxin-induced hypertension. Ancillary tests 
were done to narrow down this list. The patient’s ECG showed 
a sinus tachycardia with possible left ventricular hypertrophy 
(Figure 1). His chest radiograph was normal. His complete 
blood count, electrolytes, renal function and thyroid 
stimulating hormone were normal. His urine drug screen was 
negative. The patient was noted to have a mildly elevated 
calcium level (10.3mg/dL). 
Based on the studies performed and presentation, the 
working diagnosis for the patient was then 
pheochromocytoma. Because the patient’s hypertension 
seemed the likely etiology of his symptoms, he was treated 
with 10mg of intravenous labetalol and 0.5 inches of 2% 
nitroglycerine paste. These were chosen because of their 
immediate availability in the ED. This resolved the patient’s 
symptoms. His blood pressure subsequently decreased to 
144/86mmHg and his heart rate decreased to 71 beats/min. An 
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chest, abdomen and pelvis were ordered to look for possible 
etiologies of the hypertension, and he was admitted to the 
intensive care unit.
The patient’s echocardiogram showed evidence of 
concentric left ventricular hypertrophy, with no other 
abnormalities. His CT scan showed a 5.6 x 4.7 cm mass in the 
left pelvis along the posterior dome of the bladder, which was 
consistent with a pheochromocytoma, given its location and 
the clinical picture (Figure 2). Supporting inpatient lab studies 
revealed a plasma normetanephrine level of 4,062 pg/ml 
(normal is 0-145) and a urine norepinephrine of 3,304 ug/24 
hours (normal is 0-140). Throughout the first two days of his 
hospital stay, the patient complained of frequent headaches. 
CT and magnetic resonance image (MRI) of the head were 
ordered to exclude metastasis to the brain or intracranial bleed, 
both of which were negative. He was started on 
phenoxybenzamine while an inpatient to control his blood 
pressure, to which he responded well. 
The patient was discharged on phenoxybenzamine and 
remained using it for six weeks. He then underwent surgical 
resection of his pheochromocytoma. The mass showed 
evidence of vascular invasion and cell spindling, with three 
mitotic figures out of ten cells, which increases the malignant 
potential of his mass. The patient had a partial cystectomy 
and removal of his left vas deferens. His pathological margins 
were negative, and all resected lymph nodes showed no 
evidence of metastases. He was discharged after a brief stay 
in the hospital, during which he was hemodynamically stable. 
He was scheduled to follow up with endocrinology and 
hematology/oncology. 
DISCUSSION
Although essential hypertension is increasing in incidence 
in children (likely secondary to obesity), all hypertension in 
the pediatric population should be considered secondary to 
organic disease rather than essential until proven otherwise.1 
Hypertension in children is defined as a blood pressure greater 
than the 95th percentile for age, and is approximated by the 
formula 70 + (2 x age). Children presenting with higher blood 
pressures or at a younger age are more likely to have 
secondary causes of hypertension. Appropriate screening for 
and treatment of these diseases may reduce risk of long-term 
medical complications related to hypertension.1 Apart from 
pheochromocytoma, other reasons for secondary hypertension 
in children include primary renal disease (such as sponge 
kidney), renovascular disease (such as renal artery stenosis or 
thrombosis), congenital heart disease (such as coarctation of 
the aorta), pulmonary disease (such as bronchopulmonary 
dysplasia) and other forms of endocrine disease (i.e. 
hyperthyroidism), with renal causes being the most common.1 
Most of these etiologies can be excluded using historical and 
physical findings, as well as routine blood tests, renal 
ultrasound and echocardiography. If these causes for 
hypertension are eliminated, pheochromocytoma must be 
ruled out in the pediatric patient.
Pheochromocytoma is a paraganglioma, or tumor, that 
arises from neural crest tissue. Paragangliomas may be 
parasympathetic or sympathetic in origin, but all 
pheochromocytomas are derived from chromaffin cells and are 
therefore sympathetic.2 Because of their embryological origin, 
they are found anywhere along the sympathetic chain, from 
the base of the brain to the urinary bladder. 
Pheochromocytoma is rare, accounting for 0.05-2% of all 
cases of hypertension, and there is no gender or race 
predilection.3 Seventy-five percent of cases are sporadic.4 In 
sporadic cases, the “rule of 10s” applies: 10% are bilateral, 
10% are malignant, 10% are extra-adrenal, and of those, 10% 
are extra-abdominal. Familial cases (most commonly 
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Figure	1. The patient’s electrocardiogram showed a sinus tachy-
cardia with possible left ventricular hypertrophy upon arrival to the 
emergency department.
Figure	2. Computed tomography showed a 5.6 x 4.7 cm mass in 
the left pelvis along the posterior dome of the bladder, which was 
consistent with a pheochromocytoma, given its location and the 
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associated with the multiple endocrine neoplasia 2A and 2B 
syndromes, neurofibromatosis and Von-Hippel-Lindau 
syndrome) are bilateral half the time and malignant in 36% of 
patients.5 As many as 20% of newly diagnosed 
pheochromocytomas are in the pediatric population, in whom 
the disease is more commonly associated with these inherited 
syndromes.6-8 Extra-adrenal pheochromocytomas have a 
higher risk of malignancy than their adrenal counterparts 
(36%).5 While even “benign” pheochromocytoma is fatal if 
undiagnosed and untreated, it is potentially curable if 
diagnosed. Unfortunately, diagnosis is difficult and is typically 
delayed by about a year even in symptomatic children.9 
Approximately 50% of cases are discovered at autopsy.10
The clinical manifestations seen in pheochromocytoma 
are due to the unregulated secretion of excess catecholamines, 
mainly norepinephrine.11,12 This activates alpha-adrenergic 
receptors in vascular smooth muscle, causing hypertension. 
Vascular constriction in the skin, gastrointestinal tract, brain, 
and kidney further potentiate systemic hypertension.11,12 
Beta-adrenergic receptor activation also occurs, leading to 
increased cardiac output, with both chronotropic and inotropic 
effects. Beta activation increases renin secretion and worsens 
systemic hypertension via increased production of angiotensin 
II, antidiuretic hormone and aldosterone.11,12 Furthermore, 
insulin secretion is suppressed while glucagon secretion 
increases, leading to glycogenolysis, gluconeogenesis and 
lipolysis.13 The hypertension may be paroxysmal or sustained. 
Ultimately, malignant hypertension ensues leading to 
myocardial infarction, congestive heart failure, stroke, 
intracranial hemorrhage, papilledema or renal failure. If 
untreated, cardiovascular collapse and death follow. 
The most common presenting symptoms in both adult and 
pediatric patients with pheochromocytoma are headache 
(70-90%), palpitations (50-70%) and diaphoresis (60-
70%).7,9,14 Other common symptoms include anxiety, chest 
pain, dyspnea, fatigue, heat intolerance and focal neurologic 
deficits.7,14,15 The vast majority will have hypertension on 
exam (90-100%).14 Fever, pallor, hyperglycemia and vomiting 
are also commonly seen.9,14
Because the signs and symptoms of a pheochromocytoma 
can fit the clinical picture for many other diseases, the first and 
most important step in making the diagnosis is considering the 
disease. However, once pheochromocytoma enters the 
differential list, diagnosis can still be quite difficult as there is 
no one “best test.” Fractionated plasma metanephrines is 
considered the best initial screening exam, especially in high 
risk patients (i.e., those with positive family histories, classic 
histories or multiple endocrine tumors).16 This test can be 
skewed by certain medications, specifically tricyclic 
antidepressants and may be falsely elevated in the older 
patient population. A positive test should be confirmed with 
the highly specific 24-hour total urine metanephrine level.16,17 
Despite the diagnostic use, the test is cumbersome and 
compliance is low, especially in children. Additionally, the 
clonidine suppression test, which measures plasma 
norepinephrine and metanephrines after a 0.3mg dose of 
clonidine, has been shown to differentiate between true and 
false elevations in plasma metanephrine levels.18 
Unfortunately, none of these tests are practical in the ED.
If the provider is strongly considering a diagnosis of 
pheochromocytoma, admission for diagnostic studies is 
warranted. Asymptomatic, compliant adult patients with 
excellent follow-up could potentially be evaluated as 
outpatients, but symptomatic patients and children should be 
admitted. Once biochemical testing suggests the presence of a 
tumor, imaging studies should be ordered to locate it. Tumors 
greater than 3 cm can easily be identified on CT or MRI, yet 
both tests have their respective downfalls. CT often require 
contrast and has a higher radiation exposure, while MRIs are 
more expensive and have inferior spatial relationship when 
compared to CT.19 If no tumor is noted on preliminary imaging 
and clinical suspicion is still high, an I-MIBG study should be 
ordered. I-MIBG is a compound that resembles 
norepinephrine and is taken up by active adrenal tissue. Scans 
have a sensitivity of 77-90% and specificity of 95-100%.17,19 
Finally, while small studies have shown positron emission 
tomography to detect 100% of tumors, cost and availability 
have prevented this from becoming the first line choice.19
Well before the final diagnosis of pheochromocytoma is 
made, urgent symptomatic treatment should be started with a 
goal of controlling severe hypertension and tachycardia. 
Definitive treatment is surgical removal of the tumor; 
however, medical management pre- and intra-operatively is 
extremely important. In the ED this should consist of initial 
treatment with an alpha blocker or vasodilator, such as 
nitroprusside or hydralazine, with addition afterwards of a 
beta blocking agent to control heart rate. Labetalol is also an 
appropriate first-line choice, as it has both alpha- and beta-
blocking effects. Single drug therapy with a beta-blocker 
should be avoided because of the risk of severe, possibly fatal, 
hypertensive episodes caused by unopposed alpha-receptor 
stimulation.20 It is important to remember that, in spite of the 
hypertension, these patients require intravenous fluid 
resuscitation. Because of long-standing vasoconstriction, they 
can be profoundly dehydrated, so it is appropriate to give 
several liters of fluid with reassessment while treating the 
hypertension. Once the patient is stable, first-line medical 
therapy is an oral alpha-adrenoceptor blocker, the most 
effective of which is phenoxybenzamine. Phenoxybenzamine 
is an irreversible, long-acting alpha-adrenoceptor blocker that 
opposes extreme vasoconstriction caused by catecholamine 
surge.4 An oral beta-blocker can be added after adequate 
alpha-blockade is achieved. Lastly, metyrosine is another 
option for medical management, as it works through inhibition 
of catecholamine synthesis by blocking tyrosine hydroxylase. 
This medication has been shown to decrease clinical 
symptoms but can cause sedation, anxiety and diarrhea. 20 
All children with pheochromocytoma should be evaluated 
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for inherited endocrine syndromes. They should all have 
long-term follow up to detect recurrence and metastases as 
early as possible. Most patients with appropriate surgical 
therapy have normalization of their blood pressure, but some 
will require long-term medical therapy, as well.
In conclusion, pheochromocytoma, while extremely 
rare, is a diagnosis that should be considered in the ED in 
pediatric patients with hypertension, particularly in those 
with malignant hypertension. Although it is not necessary 
(or sometimes even possible) for the emergency physician to 
make the diagnosis definitively, it is critical that the provider 
consider this entity and facilitate timely and appropriate 
evaluation. The emergency medicine provider must also 
begin an appropriate medical treatment regimen while 
avoiding potentially harmful therapies, such as beta-blocker 
monotherapy, in order to minimize morbidity and mortality 
from this disease. 
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